Recent research have focused on the overlap of glucagon-like peptide-1|glucose-dependent insulinotropic polypeptide|GCGR activator therapies and DA neurotransmission. While GIP agonists are widely employed for managing type 2 T2DM, their unexpected impacts on reinforcement circuits, specifically influenced by dopaminergic systems, are attracting su